Weight loss supplement advertising: the claims the FTC says can't be true, the platform rules and the GLP-1 line

In weight loss supplement advertising, seven claims are off the table from the start: the FTC's Gut Check guide lists them as claims that experts agree "simply can't be true". Every other weight-loss claim needs competent and reliable scientific evidence, and the FTC calls randomized controlled trials the most reliable kind. Meta, Google and TikTok then add their own limits on age, wording and markets.

The seven weight-loss claims the FTC says can't be true

Here are the seven, in the words of the FTC's Gut Check guide. Tick each one that your ad, your VSL and your landing page stay clear of:

The FTC's seven Gut Check claims

In the words of the FTC guide (January 2014). Tick each one your copy avoids.

• Doesn't claim it causes weight loss of "two pounds or more a week for a month or more without dieting or exercise"
• Doesn't claim it "causes substantial weight loss no matter what or how much the consumer eats"
• Doesn't claim it "causes permanent weight loss even after the consumer stops using product"
• Doesn't claim it "blocks the absorption of fat or calories to enable consumers to lose substantial weight"
• Doesn't claim it safely enables consumers "to lose more than three pounds per week for more than four weeks"
• Doesn't claim it "causes substantial weight loss for all users"
• Doesn't claim it causes substantial weight loss "by wearing a product on the body or rubbing it into the skin"

0 of 7 done

The list began in 2003 as "Red Flag: Bogus Weight Loss Claims", a guide for media outlets that called the seven claims "scientifically infeasible at the current time". Announcing it, then-Chairman Muris spoke of "scientifically impossible weight-loss products" (FTC, 2003). The January 2014 update, Gut Check, says experts agree the claims "simply can't be true" and that one appearing in an ad is "likely to be a tip-off to deception" (FTC, 2014). It's addressed to publishers and broadcasters, asking them to check ads before they run, but it works just as well as a list of lines never to write.

The exact wording is easy to avoid; the paraphrase is the trap. "Melts fat while you sleep" says weight loss without dieting or exercise. "Keep it off for good" says permanent weight loss after the product stops. "Works no matter your age or metabolism" says substantial weight loss for all users, and "stops the fat in your meals so the pounds come off" says it blocks absorption. That's our reading rather than the FTC's wording, so read your own copy the way a buyer would, not the way its writer meant it.

What evidence a weight-loss claim needs

For every other weight-loss claim, the standard is the FTC's Health Products Compliance Guidance, published December 20, 2022, which replaced its 1998 advertising guide for supplements. Health-benefit claims "require substantiation in the form of competent and reliable scientific evidence", and the guidance calls randomized, controlled human clinical trials "the most reliable form of evidence". Its endnotes cite cases that applied an RCT standard to weight-loss claims in particular.

Three of its weight-loss examples are worth reading before you write a script:

• The diet behind the study (Example 8). A weight-loss supplement cites a placebo-controlled, double-blind study in which the subjects were also on a restricted-calorie diet; the ad should say so.
• The size of the effect (Example 30). A claim that a supplement will "substantially reduce body fat" is unsubstantiated when the evidence shows only a small effect that may not last.
• Before-and-after photos (Example 41). A magazine ad for a weight-loss supplement shows before-and-after photos with the line "These results are not typical", and the disclaimer isn't enough.

The guidance adds that testimonials "that report results more dramatic than users can generally expect are likely to be deceptive." It also says "structure/function", an FDA labeling term, has "no legal significance under FTC law relating to claim substantiation". So calling a line structure/function doesn't lower the evidence it needs. Our post on before-and-after photos covers the disclosure that works where "results not typical" doesn't.

Here's what that means for one fictional study. Say a brand's formula was tested for 12 weeks against a placebo, everyone in both groups followed a reduced-calorie diet, and the supplement group lost a little more weight on average than the placebo group:

One fictional study, two ways to advertise it

A fictional 12-week trial: a reduced-calorie diet in both groups, a small difference against placebo

Not supported by this studyOverstates it

• "Melts fat without dieting": everyone in the study dieted
• "Substantially reduces body fat": the effect was small (FTC Example 30)
• "Clinically proven weight loss" and nothing else: hides the diet and the size of the difference
• A best-case customer before-and-after with "results not typical": not enough (FTC Example 41)

Closer to what the study showsMatches it

• Says everyone in the study also followed a reduced-calorie diet (FTC Example 8)
• States the average difference against placebo, in pounds, next to the claim
• Says how long the study ran and that individual results vary
• Uses testimonials whose results match what buyers generally achieve

Written out with fictional numbers, a line that matches the study might read: "In a 12-week study in which everyone followed a reduced-calorie diet, people taking the formula lost an average of 2 pounds more than those taking a placebo. Individual results vary." It's less exciting than "melts fat", and that's the point: every part of it can be checked against the study.

The first line on the left would also run into Google's and TikTok's own rules, which are the next layer. The full FTC standard, with its enforcement cases, is in our post on supplement advertising rules:

How Meta, Google and TikTok treat weight-loss ads

Each platform applies its own rules on top of the law, and they draw the line in different places. Their published weight-loss rules, side by side:

Weight-loss ad rules on three platforms

What each platform's published policy says, October 2026

MetaGoogleTikTok

Meta (Facebook and Instagram)

In January 2023, Meta said its Advertising Standards already kept ads for "weight loss products and services" from people under 18, with a higher age limit in some countries (Meta, January 2023). Its standards have a health and wellness section of their own, and its current wording is what counts: read it before you write a weight-loss ad.

How Meta's rules shape a supplement campaign: Facebook ads for supplements.

Google Ads and YouTube

• No "claims of unrealistic weight loss within a specific time frame or requiring little effort"; Google's example is an ad saying you can eat whatever you want and lose 10 pounds in a month (Misrepresentation)
• No products containing ephedra or hCG "in relation to weight loss or weight control", and none that imply they are "as effective as prescription drugs" (Unapproved substances)
• Its non-exhaustive list of unapproved supplements names slimming products such as Meizitang and P57 Hoodia
• Testimonials with specific results need a visible disclaimer that results can vary

TikTok

• Any weight-loss or muscle-gain claim must target ages 18 and older (Weight Management and Body Image)
• No unrealistic results, nothing suggesting weight loss is "easy or guaranteed", and no claim that the product works alone, "without diet or exercise"
• Weight-loss supplements are listed as allowed only in ten Group 1 markets in Asia-Pacific; the US isn't named, so confirm eligibility with TikTok
• The Branded Content Policy lists weight-loss supplements among the prohibited industries for paid creator posts
• Before-and-after comparisons that may give a false or distorted impression are restricted (Misleading and false content)

The full TikTok picture: TikTok ads for supplements.

Two patterns run across them. TikTok's policy and Meta's 2023 statement both keep weight-loss ads to adults, and Google and TikTok both reject promises of unrealistic or effortless weight loss, which sit close to the first Gut Check claim. TikTok also decides by market, so a weight-loss supplement it lists as allowed in Australia may need a separate answer from TikTok for the US. A line that clears the FTC's seven can still fail a platform's review: write to the strictest platform you buy traffic from.

One gap is worth knowing about. Google's pages on health in personalized advertising don't mention weight loss, diet or obesity, so don't assume a weight-loss supplement falls into its sensitive health category, which limits the audiences you can use. A product promoted around a health condition is the case those pages describe.

GLP-1 claims: what FDA and the FTC have actually done

FDA's page on unapproved GLP-1 drugs used for weight loss says compounded drugs aren't FDA-approved or reviewed by FDA for safety, effectiveness or quality before they're marketed, and that FDA "has issued warning letters to stop the distribution of illegally marketed semaglutide and tirzepatide." These are the GLP-1 actions a supplement marketer should know about, in order; all but one concern drugs or telehealth programs:

GLP-1 weight-loss marketing: what regulators did

Every entry but the last concerns drugs or telehealth programs, not supplements

1. Oct 2, 2024Tirzepatide shortage resolvedFDA's determination, reaffirmed on December 19, 2024; compounders' transition periods followed.
2. Feb 21, 2025Semaglutide shortage resolvedFor outsourcing facilities, the transition ran until May 22, 2025.
3. Jul 14, 2025FTC complaint against NextMedA telehealth seller of GLP-1 weight-loss programs. The FTC alleged unsubstantiated claims that members lose 53 pounds, fake testimonials and before-and-after photos of people who weren't customers.
4. Sep 9, 2025FDA warning letter to GLP-1 SolutionA telehealth seller whose claims, FDA wrote, "imply that your products are the same as an FDA-approved product when they are not."
5. Dec 3, 2025Final order against NextMed$150,000 for consumer refunds, and competent and reliable evidence required for typical-results claims.
6. Feb 6, 2026FDA on compounded GLP-1 marketingCompanies cannot claim that non-FDA-approved compounded products are "generic versions or the same as drugs approved by FDA".
7. Mar 31, 2026Research peptides sold for weight lossFDA's letter to Prime Sciences: one page called a product an "Ozempic – Weight Loss Supplement", and FDA concluded "these products are unapproved new drugs."
8. Aug 24, 2026Warning letter to a "GLP-1" supplementBioDrive's "Evolv GLP-1 Biomimetic": the problem FDA named was an ingredient without adequate safety information, not the GLP-1 wording.

Three lessons for supplement copy follow from them.

FDA's claim limits are a list of what not to imply. The February 2026 announcement is written for companies selling compounded drugs, not supplements. Still, the claims it rules out, that a product is one of the "generic versions" or "the same as drugs approved by FDA", has the "same active ingredient" or is "clinically proven to produce results for the patient", are worth treating as off-limits in supplement copy too.

A label doesn't change what a product is. Prime Sciences called a research peptide an "Ozempic – Weight Loss Supplement"; FDA treated the products as unapproved new drugs anyway.

The one supplement letter here was about safety. FDA's August 2026 letter to BioDrive concerned "Evolv GLP-1 Biomimetic", a dietary supplement whose peptide ingredient FDA treated as a new dietary ingredient without adequate safety information. FDA found the product adulterated and noted the company had marketed it "despite FDA's objections due to safety concerns". The letter doesn't analyze the GLP-1 wording.

None of these cases is about the wording of a supplement ad, so the rule that governs that wording is the general one. FDA's regulation on supplement claims lists what turns a statement into a disease claim, and three of its criteria fit GLP-1 copy closely: a product that "is a substitute for a product that is a therapy for a disease", one that "augments a particular therapy or drug action", and an effect on a disease implied through "the name of the product" (21 CFR 101.93(g)).

On our reading, "a natural alternative to Ozempic", "boosts your GLP-1 shot" and a product named after the drug class all sit close to those criteria, and Google separately bars products that imply they're "as effective as prescription drugs" (Unapproved substances). A supplement can describe what its ingredients do in the body, within the limits set out in structure/function claims. It can't present itself as the drug.

Honest angles for weight loss supplement advertising

Take out the seven claims, the drug comparisons and the promises of speed or ease, and an honest ad still has material to work with:

• The routine. Show the product as part of a plan with diet and exercise. TikTok's policy and the first Gut Check claim both turn on a product that works without them.
• Appetite or fullness, if a controlled study of your formula supports that specific claim. On the label, a structure/function statement needs FDA's disclaimer and a notification to FDA within 30 days of first marketing (21 CFR 101.93), and the FTC still expects the evidence.
• The study, told straight: the diet everyone followed, the difference against placebo and how long it ran.
• The formula: what's in a serving and why each ingredient is there, in terms your evidence supports.
• Typical customers: testimonials whose results match what buyers generally achieve, with any payment or free product disclosed. If most buyers in your data lose a few pounds over two months, the customer who lost forty isn't the one to lead with.

Before a line goes into the VSL, an ad or the page, run it through four questions:

Is this weight-loss line ready to run?

One line of copy at a time

1Does the line say or imply one of the seven Gut Check claims?

YesNo

"Melts fat while you sleep" counts: it implies weight loss without dieting or exercise.

2Does it compare the product to a prescription drug, name one, or put GLP-1 in the product name?

YesNo

3Do you have competent and reliable scientific evidence for this exact claim?

YesNo

The FTC calls randomized, controlled human clinical trials the most reliable form.

4Does it promise unrealistic results in a set time, make weight loss sound easy, or credit the product alone?

YesNo

Best fit

Take the claim out

The line says or implies one of the seven claims the FTC's Gut Check guide says "simply can't be true". Remove the claim rather than trying to qualify it.

Best fit

Rewrite it without the drug

The line isn't a Gut Check claim, but it compares the product to a prescription drug, names one or puts GLP-1 in the product name. Google bars products that imply they're as effective as prescription drugs. FDA's criteria treat a product presented as a substitute for a disease therapy as making a disease claim, and on our reading a drug comparison does exactly that.

Read more: Structure/Function Claims: Rules, Examples, Disclaimer

Best fit

Hold it until the evidence exists

The line avoids the seven claims and any drug comparison, but you don't have competent and reliable scientific evidence for it. Rewrite it to say only what your evidence shows, or leave it out.

Read more: Supplement Advertising Rules: What the FTC Requires

Best fit

Fix the framing for the platforms

The line avoids the seven claims and drug comparisons and you have the evidence, but it promises unrealistic results in a set time, makes weight loss sound easy, or credits the product alone. Google's Misrepresentation policy rejects unrealistic weight loss in a set time or with little effort, and TikTok's policy rejects weight loss made to sound easy or guaranteed and products said to work without diet or exercise. Tie the claim to diet and exercise and drop the deadline.

Best fit

Ready for a final review

No Gut Check claim, no drug comparison, evidence in hand and no promise of unrealistic speed, ease or the product working alone. Check each platform's age and market rules, then have a lawyer review the final ad and page.

Before a weight-loss ad goes live

1. Check every line of the ad, the VSL and the page, paraphrases included, against the seven Gut Check claims.
2. Build an evidence file for each remaining claim: the studies, what the participants also did, the size of the effect and how long it lasted.
3. Remove drug names, GLP-1 comparisons and "works like" lines, from the product name too.
4. Replace "results not typical" with what buyers generally achieve, next to any testimonial or before-and-after.
5. Set 18-plus targeting wherever a platform requires it, and confirm TikTok eligibility for every market if the product is a weight-loss supplement.
6. Leave paid creator posts out of the TikTok plan: its Branded Content Policy lists weight-loss supplements among its prohibited industries.
7. Keep the label, the VSL and the ads saying the same thing. The VSL compliance guide covers testimonials and disclosures inside the video.
8. Have a lawyer review the final ad and page before launch.